Hōʻike ka lāʻau lapaʻau CD19 CAR-T i ka Halemai ʻo Lu Daopei i nā hopena maikaʻi loa i nā maʻi B-ALL
I loko o kahi noiʻi hoʻopaʻapaʻa i hana ʻia ma ka Halemai ʻo Lu Daopei, ua hōʻike nā mea noiʻi i nā holomua nui i ka mālama ʻana i ka maʻi leukemia lymphoblastic B (B-ALL) refractory a i hoʻihoʻi hou ʻia me ka hoʻohana ʻana i kahi CD19-directed CAR-T cell therapy. Ua hōʻike ʻia ka haʻawina, kahi i pili ai i nā maʻi 51, ʻaʻole i loaʻa i kēia ʻano hana hou ke kiʻekiʻe kiʻekiʻe o ke kala kala piha (CR) akā mālama pū kekahi i kahi ʻike palekana maikaʻi.
ʻO ka hui noiʻi, alakaʻi ʻia e Kauka C. Tong mai ke Keʻena Hematology a me Kauka AH Chang mai ka Clinical Translational Research Center ma Tongji University School of Medicine, ua noiʻi i nā hopena o ka lawelawe ʻana i kahi haʻahaʻa haʻahaʻa o nā cell CAR-T-ma kahi o 1 × 10^5/kg—hoʻohālikelike ʻia me nā ʻano kiʻekiʻe maʻamau. ʻO kēia ala i manaʻo e kaulike i ka pono therapeutic me ka hōʻemi ʻana i nā hopena ʻaoʻao koʻikoʻi, ʻoi aku ka cytokine release syndrome (CRS).
He mea koʻikoʻi nā hopena o ka haʻawina. Ma waena o ka 42 refractory / relapsed B-ALL maʻi, 36 i loaʻa iā CR a i ʻole CR me ka helu helu ʻole (CRi), aʻo nā mea maʻi ʻeiwa me ka liʻiliʻi liʻiliʻi maʻi (MRD) hiki i ka MRD negativity. Eia kekahi, ʻo ka hapa nui o nā maʻi i ʻike i ka CRS maʻalahi a me ka haʻahaʻa, me nā hihia koʻikoʻi e mālama maikaʻi ʻia ma o nā hoʻolālā hana mua.
Ua hōʻike ʻo Kauka Tong i ke koʻikoʻi o kēia haʻawina, me ka ʻōlelo ʻana, "Ua hōʻike nā hopena i ka haʻahaʻa CD19 CAR-T cell therapy, a ukali ʻia e allogeneic hematopoietic stem cell transplantation (allo-HCT), hāʻawi i kahi koho lapaʻau maikaʻi loa no nā maʻi i loaʻa. ʻAʻole hāʻawi wale kēia lāʻau lapaʻau i nā helu pane kiʻekiʻe akā hoʻohaʻahaʻa nui i ka hopena o nā hopena ʻino.
ʻO ka kūleʻa o kēia haʻawina e hōʻike ana i ka hiki o nā lāʻau lapaʻau CAR-T i hoʻopili ʻia i ka mālama ʻana i nā maʻi maʻi hematological paʻakikī. ʻO ka Halemai Lu Daopei, kaulana no kāna hana paionia i ka immunotherapy cellular, ke hoʻomau nei i ke alakaʻi i ka hoʻolako ʻana i nā lāʻau lapaʻau ʻokiʻoki no nā poʻe maʻi me nā kūlana hematologic paʻakikī.
Ke holomua nei ke aʻo ʻana, manaʻo ka hui noiʻi e pili ana i ka hoʻomaʻemaʻe hou ʻana i ka dosage a me nā protocols e hoʻomaikaʻi i nā hopena maʻi. Ua paʻi ʻia nā ʻike mai kēia haʻawina ma ka puke paiLeukemiaa hāʻawi i kahi manaʻo manaʻolana no nā maʻi B-ALL ma ka honua holoʻokoʻa.